Pharmacoepigenetics of Bipolar Disorder Treatment

NCT02374996 | Completed

• 1 other identifier: BPBIOPWSU
• Study Type: observational
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

Insulin is a hormone produced by the body to regulate blood sugar. Insulin resistance is a state when the body is not using insulin correctly, and more insulin is needed to maintain normal blood sugar. Insulin resistance is common in bipolar patients and even more common in bipolar patients treated with antipsychotics. Insulin resistance from antipsychotics can lead to type 2 diabetes, metabolic syndrome and cardiovascular disease and is known to lead to worse psychiatric outcomes (less mood stability) and lower life expectancies in bipolar disorder. Abnormal regulation of the folate cycle is known to play a role in antipsychotic-induced insulin resistance and the main endpoint to the folate cycle is the production of methyl donors for DNA methylation. DNA methylation is critical as it regulates how genes are expressed. Thus, changes in DNA methylation may play a role in the disease process of antipsychotic-induced insulin resistance. The purpose of this study is to examine the differences in the DNA methylation of candidate tissues known to have a role in the development of insulin resistance. The three groups of bipolar patients to be studied are 1) antipsychotic treated patients with impaired glucose tolerance, 2) antipsychotic treated patients with normal glucose tolerance and 3) lithium treated patients with normal glucose tolerance. Group 1 will be compared to groups 2 and 3 in order to assess how DNA methylation in the skeletal muscle and fat tissue changes due to medication effects (group 2 vs. 3) and medication side effects (group 1 vs. 2). Secondary analyses include the analysis of how fats are processed in skeletal muscle and fat tissue in relation to antipsychotic-induced insulin resistance and the correlation of DNA methylation across different tissues. The investigators hypothesize that antipsychotic-induced insulin resistance is to due changes in the way DNA is expressed (through epigenetic changes) which causes further changes in the way fats are processed in the body eventually leading to insulin resistance. This work is based on preliminary findings however further work is needed to identify the true mechanisms behind antipsychotic-induced insulin resistance and in particular, the main tissue in which this mechanism occurs.

Conditions

Antipsychotic Agents; Bipolar Disorder

Outcome Measures

Primary Outcomes (1)

• DNA methylation in skeletal muscle and adipose tissue

  The prevalence of DNA methylation of cytosine-phosphate-guanosine (CpG) Island 81 of the Fatty Acyl Coenzyme A Reductase gene will be compared amongst the groups. The is reported as % methylation

  Baseline

Secondary Outcomes (1)

• shotgun Lipidomics in skeletal muscle and adipose tissue

  Baseline

Other Outcomes (1)

• DNA methylation Across tissues

  Baseline

Study Arms (3)

APIGT

Bipolar subjects treated with antipsychotics and having impaired glucose tolerance

APNGT

Bipolar subjects treated with antipsychotics and having normal glucose tolerance

LINGT

Bipolar subjects treated with lithium and having normal glucose tolerance

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Bipolar patients treated with Lithium or an antipsychotic

You may qualify if:

• Aged 18-65 with a Bipolar Spectrum Diagnosis (Bipolar I, II or NOS)
• Currently treated with lithium or an antipsychotic as determined by a physician for at least 3 months at a stable dosage.
• Non- obese with BMI \< 30
• Able to communicate meaningfully with the investigator and legally competent to provide informed written consent.
• Females must be non-lactating, have a pregnancy test and be on acceptable birth control
• subjects will be studied in total from three groups:
• One group will consist of 35 bipolar patients currently stable on an antipsychotics with impaired glucose tolerance (2-hour postprandial plasma glucose of 140-199mg/dL).
• The second group will consist of 35 age, gender, and body composition matched bipolar patients currently stable on an antipsychotic with normal glucose tolerance (2-hour postprandial plasma glucose \<140mg/dL.
• The third group will consist of 35 age, gender and body composition matched bipolar subjects stable on lithium with normal glucose tolerance.

You may not qualify if:

• Currently diagnosed with diabetes (type I or II) or receiving treatment for diabetes. Any history of metabolic complications (weight gain, high cholesterol, high blood pressure) before taking an antipsychotic.
• Active diagnosis of alcohol or substance abuse.
• Primary relative diagnosed with type II diabetes.
• Treated with any of the following medications: a) Systemic glucocorticoids (more than 2 weeks), antineoplastic agents, transplant medications, anti-retroviral medications within 6 months prior to screening.
• Start or change of hormonal replacement therapy within 3 months prior to screening.
• History or presence of any of the following conditions
• Clinically significant heart disease (New York Heart Classification greater than grade II; more than non-specific ST-T wave changes on the EKG)
• Peripheral vascular disease (history of claudication)
• Clinically significant pulmonary disease.
• Current uncontrolled hypertension (systolic BP\>160 mmHg, diastolic BP\>100 mmHg)
• History or presence of malignancy other than basal cell or squamous cell skin cancer
• Clinically significant hematologic disease
• Any of the following abnormal laboratory values:
• Hematocrit \< 35 vol%
• Serum creatinine \> 1.6 mg/dl

Sponsors & Collaborators

• Wayne State University: lead

Study Sites (1)

Wayne State University Clinical Research Center

Detroit, Michigan, 48202, United States

Location

MeSH Terms

Conditions

Bipolar Disorder

Condition Hierarchy (Ancestors)

Bipolar and Related Disorders; Mood Disorders; Mental Disorders

Study Officials

• Kyle J Burghardt, PharmD

  Wayne State University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor

Study Record Dates

• First Submitted: February 9, 2015
• First Posted: March 2, 2015
• Study Start: November 1, 2015
• Primary Completion: September 1, 2017
• Study Completion: September 1, 2017
• Last Updated: February 14, 2018

Record last verified: 2018-02

Locations

US (1)